Objective To explore the predictive value of the lung immune prognostic index(LIPI) combined with serum soluble tumor necrosis factor receptor 2(sTNFR2) for bone marrow suppression complicated by chemotherapy in patients with non-small cell lung cancer(NSCLC). Methods A total of 92 patients with NSCLC who received chemotherapy were included and divided into a myelosuppression group(63 cases) and a non-myelosuppression group(29 cases) according to whether myelosuppression occurred after chemotherapy. Fasting venous blood was collected from all patients within 24 hours of admission. Absolute neutrophil count(Neu), total white blood cell count(WBC), and lactate dehydrogenase(LDH)were detected by an automatic analyzer. The derived neutrophil-to-lymphocyte ratio(dNLR = Neu/(WBC-Neu)) was calculated, and the LIPI score was evaluated according to the modified criteria. Serum s TNFR2 levels were detected by ELISA. The t-test/Wilcoxon rank sum test and χ2 test were used to compare baseline indicators between the two groups. Multivariate logistic regression analysis was used to identify independent risk factors. ROC curves were used to evaluate predictive efficacy. Results Serum s TNFR2 level in the myelosuppression group was(2.41±0.76) ng/mL, which was significantly higher than that in the non-myelosuppression group [(1.45±0.52) ng/mL](t = 6.235, P<0.001). LIPI-related indicators(dNLR, Neu, WBC,LDH), s TNFR2, ALT, and Cr in the myelosuppression group were all significantly higher than those in the non-myelosuppression group(t = 5.873, 4.592, 3.586, 5.012, 6.235, 2.648, 2.715, all P<0.001). High LIPI score, high serum s TNFR2, and platinum-based dual-drug chemotherapy regimens were independent risk factors for bone marrow suppression complicated by chemotherapy in NSCLC patients [OR(95%CI) = 2.518(1.423-4.451), 1.852(1.236-2.778), 2.689(1.215-5.947);P = 0.002,0.003, 0.015]. The AUCs of LIPI, serum s TNFR2, and their combination in predicting bone marrow suppression complicated by chemotherapy in NSCLC patients were 0.775, 0.816, and 0.903, respectively. The combined predictive efficacy of the two was superior to that of each individual(differences were compared using the De Long method)(Z = 2.345, 1.987; P = 0.019,0.047). Conclusion The LIPI score combined with serum s TNFR2 can effectively enhance the predictive efficacy of bone marrow suppression during chemotherapy in NSCLC patients, providing a precise basis for clinical risk stratification.

Objective To investigate the relationship between the co-expression of Cyclin D1/c-Myc and the molecular typing and prognosis of diffuse large B-cell lymphoma(DLBCL). Methods Tissue specimens and clinical data of 102 patients with DLBCL admitted to the Department of Hematology of the First Affiliated Hospital of Xinjiang Medical University from January 2021 to January 2023 were retrospectively collected. Immunohistochemistry was used to detect the expression of Cyclin D1 and c-Myc in DLBCL lymph node tissues, and patients with Cyclin D1/c-Myc co-expression were statistically analyzed. The chi-square test and Phi coefficient were used to analyze the relationship between Cyclin D1/c-Myc coexpression and DLBCL molecular typing. All patients underwent 6 cycles of R-CHOP treatment and were followed up for 2 years after treatment to record progression-free survival. Patients were divided into a poor prognosis group and a good prognosis group. Progression-free survival was compared between patients with and without Cyclin D1/c-Myc co-expression. General data, DLBCL molecular typing, and Cyclin D1/c-Myc expression were compared between patients with different prognoses.Cox regression analysis was used to analyze factors influencing poor prognosis in DLBCL. Results Among 102 DLBCL patients, 32(31.37%) showed positive expression of Cyclin D1, 45(44.12%) showed positive expression of c-Myc, and 21(20.59%) showed co-expression of Cyclin D1/c-Myc. The proportion of Cyclin D1/c-Myc co-expression in non-germinal center B-cell-like(non-GCB) subtypes was significantly higher than that in GCB subtypes, with a statistically significant difference(χ2/P = 5.346/0.021). The chi-square test results showed that Cyclin D1/c-Myc co-expression was negatively correlated with DLBCL molecular typing(Phi coefficien P =-0. 229/0. 021). The median progression-free survival time of the 102 DLBCL patients was 21.4 months, with 29 cases in the poor prognosis group and 73 cases in the good prognosis group. According to the Log-rank test, the survival time of patients with Cyclin D1/c-Myc co-expression was significantly shorter than that of patients without co-expression, with a statistically significant difference(χ2/P = 10.207/0.001). The International Prognostic Index(IPI) score, proportion of non-GCB subtypes, and proportion of Cyclin D1/c-Myc co-expression in the poor prognosis group were all significantly higher than those in the good prognosis group(t/P = 6.015/<0.001, χ2/P = 7.021/0.008,24.027/<0.001). High IPI score, non-GCB subtype, and Cyclin D1/c-Myc co-expression were independent risk factors for poor prognosis in DLBCL patients [HR(95%CI) = 2.052(1.333-3.158), 2.969(1.197-7.363), 2.880(1.240-6.690)]. Conclusion Cyclin D1/c-Myc co-expression is associated with the molecular typing and prognosis of DLBCL. Both Cyclin D1/c-Myc co-expression and non-GCB subtype are factors contributing to poor prognosis in DLBCL patients.

Objective To evaluate the utility of four novel thrombosis biomarkers—thrombin-antithrombin complex(TAT), plasmin-α2-plasmin inhibitor complex(PIC), thrombomodulin(TM), and tissue plasminogen activator-plasminogen activator inhibitor complex(t-PAIC)—in assessing thrombosis risk in surgical patients with malignant tumors. Methods We enrolled 284 patients with malignant tumors who underwent surgery at the Gynecology and Surgery Departments of Wenzhou Central Hospital between January 2024 and August 2025. Participants were categorized into a thrombosis group(n = 28) and a non-thrombosis group(n = 256) based on postoperative thrombosis incidence. Preoperative and postoperative levels of the four biomarkers were compared, and demographic and clinical characteristics were collected. Multivariate logistic regression identified independent risk factors for thrombosis, which were incorporated into a predictive model. The model' s discriminatory power was assessed using receiver operating characteristic(ROC) curve analysis and the area under the curve(AUC). Results The thrombosis group exhibited significantly higher levels of PIC and TAT both preoperatively and on postoperative day 7 compared to the non-thrombosis group(PIC:t = 2.104,2.555,P = 0.036, 0.011; TAT:t = 2.623, 3.264,P = 0.009, 0.001). Logistic regression confirmed that elevated preoperative and postoperative(day 7) levels of PIC and TAT were independent risk factors for thrombosis [PIC:OR(95%CI) = 1.12-46.429, 1.00-13.508; TAT:OR(95%CI) = 1.276-4.298, 1.073-1.459]. The predictive model incorporating these factors achieved an AUC of 0.782. Conclusion Elevated perioperative levels of PIC and TAT are associated with an increased risk of thrombosis in patients with malignant tumors. The prediction model based on these biomarkers demonstrates modest but valuable predictive ability for postoperative thrombosis in this patient population.

Objective To investigate the effects of Castor zinc finger 1(CASZ1) and basic helix-loop-helix transcription factor TAL1 expression in bone marrow tissue of children with acute lymphoblastic leukemia(ALL) on maintaining oral 6-mercaptopurine(6-MP) tolerance during chemotherapy. Methods Clinical data of 94 children with ALL who underwent 6-MP + cyclophosphamide + cytarabine(CAT) chemotherapy in the Department of Pediatric Hematology and Oncology of Xingtai People' s Hospital from January 2022 to February 2024 were selected, and 40 children with non-malignant hematological diseases and normal bone marrow were selected as the control group. Quantitative real-time PCR was used to detect the expression of CASZ1 and TAL1 in bone marrow tissue of children with ALL. Factors influencing 6-MP tolerance during maintenance chemotherapy and the value of CASZ1 and TAL1 expression in evaluating 6-MP chemotherapy tolerance were statistically analyzed. Results The relative expression levels of CASZ1 and TAL1 in bone marrow tissue of the ALL group were(3.24±0.54) and(2.98±0.42), respectively, which were significantly higher than those in the control group(0.89± 0.20)and(0.91±0.18)(t = 26.706, 29.722, both P<0.001). The expression of CASZ1 and TAL1 in ALL bone marrow tissue was positively correlated(r = 0.667,P<0.001). The expression levels of CASZ1 and TAL1 in bone marrow tissue of children with ALL were significantly higher in the high-risk group than in the low-risk group(t = 12.055, 13.497, both P<0.001). There were no statistically significant differences in the expression of these two markers with respect to gender, age, treatment regimen, immunophenotype, infection status, red blood cell transfusion status, platelet count, or human granulocyte colony-stimulating factor(all P>0.05). High levels of CASZ1 and TAL1 were risk factors for 6-MP chemotherapy intolerance in children with moderate-to-high clinical risk ALL [OR(95%CI) = 1.508(1.188-1.916), 1.377(1.123-1.688), 1.359(1.085-1.703)]. The AUCs for bone marrow CASZ1 expression, TAL1 expression, and their combination in predicting 6-MP chemotherapy tolerance were0.878, 0.811, and 0.934, respectively. The combination of the two was superior to their individual predictive values(Z = 4.611,5.222, both P<0.001). The durations of white blood cell count<1×109/L, absolute neutrophil count<0.5×109/L, and platelet count<25×109/L in ALL children with high expression of bone marrow CASZ1 and TAL1 were all significantly longer than those in the low expression groups(t = 12.426, 7.562, 16.606, all P<0.05). Conclusion Upregulation of CASZ1 and TAL1 expression in bone marrow tissue of children with ALL is associated with 6-MP tolerance and may serve as novel indicators for evaluating bone marrow suppression.